Aurobindo receives UK MHRA approval

Aurobindo Pharma Ltd''s Unit XII facility at Hyderabad has received approval from the UK''s Medicines and Healthcare products Regulatory Agency (UK MHRA) to manufacture formulations for the UK Market.

This facility is among Aurobindo Pharma''s largest manufacturing plants and manufactures the high-end betalactum range. Spread over 15,228 sq meters, the plant can manufacture dry powder injectables, powders for oral suspensions, tablets and capsules.

This unit also has also been certified by several overseas health bodies including the US FDA, South African MCC and Brazilian ANVISA besides meeting the ISO norms. Aurobindo Pharma says that it has filed several dossiers with European authorities for its APIs and formulations.

Earlier, the UK MHRA had also approved the first formulation of the company''s sertraline. With the latest approval by the UK MHRA''s formulation facility, Aurobindo Pharma says establishing a presence in the regulated markets has been smoothened.